AEON Biopharma’s Strategic Advancements Propel Stock Surge
In a notable development, AEON Biopharma, Inc. (NYSE: AEON) saw a significant increase in its stock value, climbing 32.08% to close the week at $1.40 per share. This surge followed the company’s announcement of plans to initiate a pivotal clinical study for its leading candidate, ABP-450 injection, aimed at treating cervical dystonia (CD). AEON Biopharma […]